Patents by Inventor Charles-Henry Fabritius
Charles-Henry Fabritius has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20230255966Abstract: The present invention is inter alia concerned with a combination of a CBP/p300 bromodomain inhibitor and an EGFR inhibitor for use in the treatment of a patient suffering from NSCLC, wherein the NSCLC exhibits an oncogenic alteration in the EGFR.Type: ApplicationFiled: June 24, 2021Publication date: August 17, 2023Applicant: TOLREMO THERAPEUTICS AGInventors: Stefanie Flückiger-Mangual, Dorothea Gruber, Thomas Bohnacker, Martin Schwill, Debora Schmitz-Rohmer, Charles-Henry Fabritius, Sara Laudato
-
Publication number: 20230233558Abstract: The present invention is inter alia concerned with (i) a combination of a CBP/p300 bromodomain inhibitor and a KRAS inhibitor for use in the treatment of a patient suffering from cancer, wherein the cancer exhibits an oncogenic alteration in the KRAS; (ii) a kit comprising (a) a pharmaceutical dosage form comprising a CBP/p300 bromodomain inhibitor and (b) a pharmaceutical dosage form comprising a KRAS inhibitor, and (iii) a pharmaceutical dosage form comprising a CBP/p300 bromodomain inhibitor and a a KRAS inhibitor.Type: ApplicationFiled: June 24, 2021Publication date: July 27, 2023Applicant: TOLREMO THERAPEUTICS AGInventors: Stefanie Flückiger-Mangual, Dorothea Gruber, Thomas Bohnacker, Martin Schwill, Debora Schmitz-Rohmer, Charles-Henry Fabritius, Sara Laudato
-
Publication number: 20230076506Abstract: The present invention relates to compounds of formula (I) and salts, stereoisomers, tautomers or N-oxides thereof that are useful as modulators of STING (Stimulator of Interferon Genes). The present invention further relates to the compounds of formula (I) for use as a medicament and to a pharmaceutical composition comprising said compounds.Type: ApplicationFiled: December 11, 2020Publication date: March 9, 2023Applicant: RYVU THERAPEUTICS S.A.Inventors: Magdalena Izabela ZAWADZKA, Luigi Piero STASI, Maciej Krzysztof ROGACKI, Grzegorz Wojciech CWIERTNIA, Lukasz Piotr DUDEK, Agnieszka Justyna GIBAS, Anna RAJDA, Charles-Henry FABRITIUS, Adam RADZIMIERSKI, Tushar Ravindra MAHAJAN, Marcin Wojciech LES, Karol ZUCHOWICZ, Marek WRONOWSKI, David Jörg SYNAK, Sundara Raghuram TANGIRALA
-
Publication number: 20230064948Abstract: The present invention relates to a compound of formula (I), optionally in the form of a pharmaceutically acceptable salt, solvate, cocrystal, tautomer, racemate, enantiomer, or diastereomer or mixture thereof: formula (I) and to pharmaceutical compositions comprising a compound of formula (I), as well as to the use of a compound of formula (I), or a pharmaceutically acceptable salt, solvate, cocrystal, tautomer, racemate, enantiomer, or diastereomer or mixture thereof, in the treatment of cancer. Further aspects of the present invention include combination therapies in which a compound of formula (I), as well as to the use of a compound of formula (I), or a pharmaceutically acceptable salt, solvate, cocrystal, tautomer, racemate, enantiomer, or diastereomer or mixture thereof, is used in combination with a known anti-cancer agent.Type: ApplicationFiled: October 1, 2020Publication date: March 2, 2023Applicant: Tolremo Therapeutics AGInventors: Stefanie Flückiger-Mangual, Dorothea Gruber, Rutger Folmer, Koen F.W. Hekking, Johan J.N. Veerman, Martijn Eerland, Charles-Henry Fabritius
-
Publication number: 20230055741Abstract: The present invention relates to compound-linker constructs and antibody-drug-conjugates of compounds of formula (I) that are useful as modulators of STING (Stimulator of Interferon Genes).Type: ApplicationFiled: December 11, 2020Publication date: February 23, 2023Applicant: RYVU THERAPEUTICS S.A.Inventors: Magdalena Izabela ZAWADZKA, Luigi Piero STASI, Maciej Krzysztof ROGACKI, Grzegorz Wojciech CWIERTNIA, Lukasz Piotr DUDEK, Agnieszka Justyna GIBAS, Anna RAJDA, Charles-Henry FABRITIUS, Adam RADZIMIERSKI, Tushar Ravindra MAHAJAN, Marcin Wojciech LES, Karol ZUCHOWICZ, Marek WRONOWSKI, David Jörg SYNAK, Sundara Raghuram TANGIRALA
-
Publication number: 20220402898Abstract: The present invention relates to compounds of formula (I) and salts, stereoisomers, tautomers or N-oxides thereof that are useful as modulators of STING (Stimulator of Interferon Genes). The present invention further relates to the compounds of formula (I) for use as a medicament and to a pharmaceutical composition comprising said compounds.Type: ApplicationFiled: June 12, 2019Publication date: December 22, 2022Applicant: RYVU THERAPEUTICS S.A.Inventors: Monika Patrycja DOBRZANSKA, Magdalena Izabela ZAWADZKA, Adam RADZIMIERSKI, Grzegorz Witold TOPOLNICKI, Grzegorz Wojciech CWIERTNIA, Tushar Ravindra MAHAJAN, Charles-Henry FABRITIUS, Stefan CHMIELEWKSI, Karolina Maria GLUZA, Jose ALVAREZ, Maciej Krzysztof ROGACKI, Magdalena MROCZKOWSKA
-
Publication number: 20220251082Abstract: The present invention relates to compounds of formula (I) and salts, stereoisomers, tautomers or N-oxides thereof that are useful as modulators of STING (Stimulator of Interferon Genes). The present invention further relates to the compounds of formula (I) for use as a medicament and to a pharmaceutical composition comprising said compounds.Type: ApplicationFiled: June 12, 2020Publication date: August 11, 2022Applicant: RYVU THERAPEUTICS S.A.Inventors: Magdalena Izabela ZAWADZKA, Luigi Piero STASI, Maciej Krzysztof ROGACKI, Grzegorz Wojciech CWIERTNIA, Lukasz Piotr DUDEK, Monika Patrycja DOBRZANSKA, Grzegorz Witold TOPOLNICKI, Agnieszka Justyna GIBAS, Anna RAJDA, Sylwia SUDOL, Karolina Maria GLUZA, Charles-Henry FABRITIUS
-
Patent number: 11345669Abstract: The present disclosure relates to compounds of Formula (I): and to their pharmaceutically acceptable salts, pharmaceutical compositions, methods of use, and methods for their preparation. The compounds disclosed herein inhibit the maturation of cytokines of the IL-1 family by inhibiting inflammasomes and may be used in the treatment of disorders in which inflammasome activity is implicated, such as inter alia autoinflammatory and autoimmune diseases and cancers.Type: GrantFiled: March 12, 2018Date of Patent: May 31, 2022Assignee: NodThera LimitedInventors: David Harrison, Alan Paul Watt, Nicolas Boutard, Charles-Henry Fabritius, Michal Galezowski, Piotr Kowalczyk, Oleksandr Levenets, Jakub Woyciechowski
-
Publication number: 20200369665Abstract: The present invention relates to the compound of formula (I) and salts, stereoisomers, tautomers, isotopologues, or N-oxides thereof. The present invention is further concerned with the use of such a compound or salt, stereoisomer, tautomer, isotopologues, or N-oxide thereof as medicament and a pharmaceutical composition comprising said compound.Type: ApplicationFiled: June 29, 2018Publication date: November 26, 2020Applicant: RYVU THERAPEUTICS S.A.Inventors: Aneta BOBOWSKA (NÉE WITKOWSKA), Michal GALEZOWSKI, Mateusz NOWAK, Claude COMMANDEUR, Joanna SZEREMETA-SPISAK, Marcin NOWOGRODZKI, Alicja OBARA, Anna DZIELAK, Iwona LOZINSKA, Marcelina DUDEK (NÉE SEDLAK), Anita ` JANIGA, Jacek REUS, Marek WRONOWSKI, Magdalena ZASTAWNA, Adam RADZIMIERSKI, Mateusz SWIRSKI, Julian ZACHMANN, Charles-Henry FABRITIUS, Roderick Alan PORTER, Joanna FOGT
-
Publication number: 20200131141Abstract: The present disclosure relates to compounds of Formula (I): and to their pharmaceutically acceptable salts, pharmaceutical compositions, methods of use, and methods for their preparation. The compounds disclosed herein inhibit the maturation of cytokines of the IL-1 family by inhibiting inflammasomes and may be used in the treatment of disorders in which inflammasome activity is implicated, such as inter alia autoinflammatory and autoimmune diseases and cancers.Type: ApplicationFiled: March 12, 2018Publication date: April 30, 2020Inventors: David HARRISON, Alan Paul WATT, Nicolas BOUTARD, Charles-Henry FABRITIUS, Michal GALEZOWSKI, Piotr KOWALCZYK, Oleksandr LEVENETS, Jakub WOYCIECHOWSKI
-
Patent number: 10577365Abstract: The present invention relates to the compound of formula (I) and salts, stereoisomers, tautomers or N-oxides thereof. The present invention is further concerned with the use of such a compound or salt, stereoisomer, tautomer or N-oxide thereof as medicament and a pharmaceutical composition comprising said compound.Type: GrantFiled: December 20, 2017Date of Patent: March 3, 2020Assignees: Felicitex Therapeutics, Inc., Selvita S.A.Inventors: Agnieszka Dreas, Charles-Henry Fabritius, Andrzej Dzienia, Anna Buda, Michal Galezowski, Georgiy Kachkovskyi, Urszula Kulesza, Katarzyna Kucwaj-Brysz, Agnieszka Szamborska-Gbur, Wojciech Czardybon, Maria Vilenchik, Michael Frid, Alexandra Kuznetsova
-
Publication number: 20180305331Abstract: Disclosed in the present application is a compound of formula (I) as defined herein as well as a pharmaceutical composition comprising said compound. Further disclosed in the present application is the use of such pharmaceutical compositions for treating diseases, namely inter alia for use in the treatment of cancer, metabolic, inflammatory, autoimmune and viral diseases. The compounds disclosed herein are inhibitors of MNK1 and/or MNK2 kinases.Type: ApplicationFiled: October 20, 2016Publication date: October 25, 2018Applicant: SELVITA S.A.Inventors: Tomasz RZYMSKI, Mariusz MILIK, Krzysztof BRZOZKA, Charles-Henry FABRITIUS, Katarzyna KUCWAJ-BRYSZ, Urszula KULESZA, Ewelina WINCZA, Agnieszka DREAS, Michal GALEZOWSKI
-
Publication number: 20180179199Abstract: The present invention relates to the compound of formula (I) and salts, stereoisomers, tautomers or N-oxides thereof. The present invention is further concerned with the use of such a compound or salt, stereoisomer, tautomer or N-oxide thereof as medicament and a pharmaceutical composition comprising said compound.Type: ApplicationFiled: December 20, 2017Publication date: June 28, 2018Applicants: Felicitex Therapeutics, Inc., Selvita S.A.Inventors: Agnieszka Dreas, Charles-Henry Fabritius, Andrzej Dzienia, Anna Buda, Michal Galezowski, Georgiy Kachkovskyi, Urszula Kulesza, Katarzyna Kucwaj-Brysz, Agnieszka Szamborska-Gbur, Wojciech Czardybon, Maria Vilenchik, Michael Frid, Alexandra Kuznetsova
-
Publication number: 20160009697Abstract: Compounds of formula (I), wherein X, Y, Z, R1-R7, m and n are as defined herein, exhibit 5-HT6 antagonistic activity and are thus useful for the treatment of certain CNS disorders. Methods of use of said compounds are also provided.Type: ApplicationFiled: February 20, 2014Publication date: January 14, 2016Inventors: Charles-Henry FABRITIUS, Michal GALEZOWSKI, Marcin KROL, Mateusz NOWAK
-
Patent number: 9221838Abstract: The invention relates to a series of compounds with particular activity as inhibitors of the serine-threonine kinase AKT. Also provided are pharmaceutical compositions comprising same as well as methods for treating cancer.Type: GrantFiled: December 23, 2010Date of Patent: December 29, 2015Assignee: ALMAC DISCOVERY LIMITEDInventors: Lixin Zhang, Graham Peter Trevitt, Hugues Miel, Frank Burkamp, Timothy Harrison, Andrew John Wilkinson, Charles-Henry Fabritius
-
Publication number: 20130116243Abstract: The invention relates to a series of compounds with particular activity as inhibitors of the serine-threonine kinase AKT. Also provided are pharmaceutical compositions comprising same as well as methods for treating cancer.Type: ApplicationFiled: December 23, 2010Publication date: May 9, 2013Applicant: ALMAC DISCOVERY LIMITEDInventors: Lixin Zhang, Graham Peter Trevitt, Hugues Miel, Frank Burkamp, Timothy Harrison, Andrew John Wilkinson, Charles-Henry Fabritius